PMID- 33728838
OWN - NLM
STAT- MEDLINE
DCOM- 20211213
LR  - 20211214
IS  - 1764-1489 (Print)
IS  - 1764-1489 (Linking)
VI  - 53
IP  - 3
DP  - 2021 May
TI  - Severe asthma management in the era of biologics: insights of the Italian 
      Registry on Severe Asthma (IRSA).
PG  - 103-114
LID - 10.23822/EurAnnACI.1764-1489.196 [doi]
AB  - Background. The Italian Registry on Severe Asthma (IRSA) is the most recent and 
      largestregistry in Italy. Objective. To improve the knowledge on the clinical and 
      biological features of severe asthma (SA), and to monitor its treatments. 
      Methods. To analyze clinical,functional, inflammatory, and treatment 
      characteristics of severe asthmatics from the IRSA registry. Results. 851 
      subjects were enrolled. 31.8% and 64.5% of patients were submitted to oral 
      corticosteroids (OCS), and monoclonal antibodies (MABs), respectively. At least 
      tw ocomorbidities affected 77.4% patients. Asthma was uncontrolled in 62.2% 
      patients. Uncontrolled patients had a higher frequency of exacerbations, and 
      hospitalization, showing a highere osinophilic phenotype, a greater use of OCS, 
      and being treated with MAB less frequently. However, uncontrolled patients 
      treated with MAB had a lower use of OCS and a lower rateof hospitalization. 
      Comparing SA patients with atopy and without atopy, the latter showeda greater 
      use of OCS, and more frequent nasal polyposis and osteoporosis. Among SA patients 
      with atopy treated with MAB, 36% were on a treatment targeting the IL-5 pathway. 
      Conclusions and clinical relevance. This study shows the features of the greatest 
      Italian registryof SA patients, revealing at the time of enrollment a poor 
      disease control, and the use of OCSand MABs in about one third and two thirds of 
      patients, respectively. SA is a complex diseasethat requires a more precise 
      phenotyping and a greater disease control.
FAU - Bilo, M B
AU  - Bilo MB
AD  - Department of Clinical and Molecular Sciences, Universita Politecnica delle 
      Marche, Italy.
AD  - Allergy Unit, Department of Internal Medicine, University Hospital Ospedali 
      Riuniti di Ancona, Italy.
FAU - Antonicelli, L
AU  - Antonicelli L
AD  - Allergy Unit, Department of Internal Medicine, University Hospital Ospedali 
      Riuniti di Ancona, Italy.
FAU - Carone, M
AU  - Carone M
AD  - Division of Pulmonary Disease, Istituti Clinici Scientifici Maugeri Spa SB, 
      Pavia, and IRCCS of Bari, Bari, Italy.
FAU - De Michele, F
AU  - De Michele F
AD  - Pneumology I and Respiratory Pathophysiology Unit, A. Cardarelli Hospital, 
      Naples, Italy.
FAU - Menzella, F
AU  - Menzella F
AD  - Pneumology Unit, Department of Medical Specialties, Arcispedale Santa Maria 
      Nuova, Azienda USL di Reggio Emilia-IRCCS, Reggio Emilia, Italy.
FAU - Musarra, A
AU  - Musarra A
AD  - Department of Allergology, Casa della Salute di Scilla, Scilla, Reggio Calabria, 
      Italy.
FAU - Tognella, S
AU  - Tognella S
AD  - Respiratory Unit, Mater Salutis Hospital, AULSS 9 Scaligera, Legnago, Verona, 
      Italy.
FAU - Vaghi, A
AU  - Vaghi A
AD  - Respiratory Unit, ASST-Rhodense, Garbagnate Milanese, Milan, Italy.
FAU - Micheletto, C
AU  - Micheletto C
AD  - Pulmonary Unit, Integrated University Hospital of Verona, Verona, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210316
PL  - Italy
TA  - Eur Ann Allergy Clin Immunol
JT  - European annals of allergy and clinical immunology
JID - 101466614
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Biological Products)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
CIN - Eur Ann Allergy Clin Immunol. 2021 May;53(3):99-102. PMID: 33908224
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Adult
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Asthma/*drug therapy/epidemiology
MH  - Biological Products/*therapeutic use
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Italy/epidemiology
MH  - Male
MH  - Middle Aged
MH  - Nasal Polyps/drug therapy/immunology
MH  - Registries
MH  - Rhinitis/epidemiology/immunology
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Asthma
OT  - IgE
OT  - biologics
OT  - eosinophils
OT  - registry
EDAT- 2021/03/18 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/03/17 07:31
PHST- 2021/03/18 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/03/17 07:31 [entrez]
AID - 10.23822/EurAnnACI.1764-1489.196 [doi]
PST - ppublish
SO  - Eur Ann Allergy Clin Immunol. 2021 May;53(3):103-114. doi: 
      10.23822/EurAnnACI.1764-1489.196. Epub 2021 Mar 16.